Perspective Therapeutics (NYSE:CATX) Shares Gap Down on Analyst Downgrade

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) gapped down prior to trading on Tuesday after Oppenheimer lowered their price target on the stock from $19.00 to $17.00. The stock had previously closed at $12.09, but opened at $11.00. Oppenheimer currently has an outperform rating on the stock. Perspective Therapeutics shares last traded at $12.36, with a volume of 91,704 shares.

A number of other analysts also recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of Perspective Therapeutics in a research report on Friday, June 14th. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Finally, Bank of America assumed coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $20.40.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, Director Lori A. Woods acquired 4,587 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was acquired at an average price of $10.90 per share, with a total value of $49,998.30. Following the transaction, the director now directly owns 159,985 shares in the company, valued at $1,743,836.50. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Lori A. Woods acquired 4,587 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average cost of $10.90 per share, for a total transaction of $49,998.30. Following the purchase, the director now directly owns 159,985 shares in the company, valued at $1,743,836.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert F. Williamson III acquired 3,003 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was purchased at an average cost of $13.30 per share, for a total transaction of $39,939.90. Following the acquisition, the director now owns 36,879 shares in the company, valued at $490,490.70. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 30,814 shares of company stock worth $385,487. 3.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently bought and sold shares of the stock. ZWJ Investment Counsel Inc. bought a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $26,000. Simplicity Wealth LLC acquired a new stake in Perspective Therapeutics in the first quarter worth approximately $40,000. Bleakley Financial Group LLC bought a new position in Perspective Therapeutics during the 1st quarter valued at $40,000. Victory Capital Management Inc. acquired a new position in shares of Perspective Therapeutics during the 2nd quarter valued at $117,000. Finally, RIA Advisory Group LLC raised its stake in shares of Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after buying an additional 99,293 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Stock Up 1.5 %

The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $11.90.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The business had revenue of $0.33 million during the quarter. On average, research analysts forecast that Perspective Therapeutics, Inc. will post -1.02 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.